E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers P > Headlines for Par Pharmaceutical Cos., Inc. > News item
Published on 7/19/2006 in the Prospect News Biotech Daily.

Par Pharmaceutical gets OK to market meloxicam for osteoarthritis

By Jennifer Chiou

New York, July 19 - Par Pharmaceutical Cos., Inc. announced it received final approval from the FDA for its Abbreviated New Drug Application for meloxicam tablets.

Meloxicam, for osteoarthritis, is the generic version of Boehringer Ingelheim's Mobic.

Woodcliff Lake, N.J.-based Par develops generic drugs and branded pharmaceuticals for specialty markets.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.